Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
16791
Cancer Research UK - United Kingdom
16186
Cancer Research UK - United Kingdom
17680
Cancer Research UK - United Kingdom
8968
Cancer Research UK - United Kingdom
15957
Cancer Research UK - United Kingdom
16812
Cancer Research UK - United Kingdom
11883
Cancer Research UK - United Kingdom
08/29/02
Department of Health - United Kingdom
PubMed
27497070
DOI
10.1093/carcin/bgw080
PII: bgw080
Knihovny.cz E-zdroje
- MeSH
- adenokarcinom genetika patologie MeSH
- alfa-katenin genetika MeSH
- celogenomová asociační studie * MeSH
- duktální karcinom slinivky břišní genetika patologie MeSH
- genetická predispozice k nemoci MeSH
- genotyp MeSH
- jednonukleotidový polymorfismus MeSH
- lidé středního věku MeSH
- lidé MeSH
- přežití bez známek nemoci MeSH
- prognóza MeSH
- protein PEBP2alfaA genetika MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- alfa-katenin MeSH
- CTNNA2 protein, human MeSH Prohlížeč
- protein PEBP2alfaA MeSH
- RUNX2 protein, human MeSH Prohlížeč
Germline genetic variability might contribute, at least partially, to the survival of pancreatic ductal adenocarcinoma (PDAC) patients. Two recently performed genome-wide association studies (GWAS) on PDAC overall survival (OS) suggested (P < 10(-5)) the association between 30 genomic regions and PDAC OS. With the aim to highlight the true associations within these regions, we analyzed 44 single-nucleotide polymorphisms (SNPs) in the 30 candidate regions in 1722 PDAC patients within the PANcreatic Disease ReseArch (PANDoRA) consortium. We observed statistically significant associations for five of the selected regions. One association in the CTNNA2 gene on chromosome 2p12 [rs1567532, hazard ratio (HR) = 1.75, 95% confidence interval (CI) 1.19-2.58, P = 0.005 for homozygotes for the minor allele] and one in the last intron of the RUNX2 gene on chromosome 6p21 (rs12209785, HR = 0.88, 95% CI 0.80-0.98, P = 0.014 for heterozygotes) are of particular relevance. These loci do not coincide with those that showed the strongest associations in the previous GWAS. In silico analysis strongly suggested a possible mechanistic link between these two SNPs and pancreatic cancer survival. Functional studies are warranted to confirm the link between these genes (or other genes mapping in those regions) and PDAC prognosis in order to understand whether these variants may have the potential to impact treatment decisions and design of clinical trials.
ARC NET Centre for Applied Research on Cancer University and Hospital Trust of Verona Verona Italy
Department of Digestive Tract Diseases Medical University of Łódź Łódź Poland
Department of Gastroenterology Lithuanian University of Health Sciences Kaunas Lithuania
Department of Surgery Gastroenterology and Oncology University of Padua Padua Italy
Department of Translational Research and New Technologies in Medicine and Surgery and
Digestive and Liver Disease Unit 'Sapienza' University of Rome Rome Italy
Genomic Epidemiology Group German Cancer Research Center Heidelberg Germany
Oncological Department ASL 1 Massa Carrara Massa Carrara Italy
Pancreas Unit Department of Digestive Disease Sant'Orsola Malpighi Hospital Bologna Italy
Transplant Surgery Department Institute for Clinical and Experimental Medicine Prague Czech Republic
Citace poskytuje Crossref.org